🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

In-depth examination of role of Tafamidis in treatment of ATTR-CM by Sumeet Singh Mitter, MD, MSc, Remior-Perez in editorial accompanying Pablo Garcia-Pavia et al. analysis of survival in THAOS registry patients treated with tafamidis. Journal of Cardiac Failure clinicalkey.com/#!/content/jou… clinicalkey.com/#!/content/jou…

Amazing GoRedforWomen AHA Science day at Inova Schar Heart and Vascular with the best colleagues in business InovaCVfellows Inova JaredSpitzMD Lily N Dastmalchi DO, MA Olayinka J. Agboola Sharmaine M Jason Bonomo Sam Sender, MSN, CRNP, FNP-BC Jamie Kennedy

Alarmingly, RFK Jr has been confirmed as HHS Secretary. The lone Republican vote against him? Senator Mitch McConnell, a polio survivor.

Guidance from the best team with tremendous outcomes in Critical Care and HF. Fantastic work in Circulation on this AHA Science scientific statement by Shashank Sinha, MD, MSc, FACC, FAHA, FHFSA and colleagues Vanessa Blumer, MD, FACC Inova Schar Heart and Vascular Mitchell Psotka Jamie Kennedy Sumeet Singh Mitter, MD, MSc Palak Shah Christopher O'Connor Shashank Desai

Pablo Garcia-Pavia Robert Mentz, MD Anu Lala-Trindade HFSA Ashish Correa Alexander Hajduczok, MD 🇺🇦🙏 Jennifer Maning, DO Elena Donald Andrew J Sauer MD Shashank Sinha, MD, MSc, FACC, FAHA, FHFSA In the accompanying editorial, the authors highlight additional agents entering the therapeutic landscape: TTR stabilizers, gene silencers/editors & TTR depleting agents. Real world data, accessibility & affordability will be key for implementation. 🔗bit.ly/4kwcblH

A monumental day for the #ATTR #amyloidosis field: #Vutrisiran is now FDA approved for ATTR-CM! The landmark #HELIOS-B trial hit 10/10 prespecified endpoints including improved all-cause mortality. Congratulations to everyone who contributed to the development/approval, and a

So glad to have another medication for our patients with TTR amyloid. Sumeet Singh Mitter, MD, MSc

A further dive into the primary efficacy endpoint in ATTRibute-CM #ACC25 #CardioTwitter #MEDIQACC25

Further analysis from ATTRIBUTE-CM utilizing different NTproBNP cut offs as a marker of disease severity, and evaluating outcomes/consistency of treatment effect #ACC25 #CardioTwitter ##MEDIQACC25

Critical data - while bone scintigraphy has resulted in a massive improvement in our diagnostic abilities in transthyretin amyloidosis, it remains insufficient with significant limitations. In this report, patients with L58H variant had closed to 90% false negative PYP scans. In

🔴 Early Increase in Serum TTR by Acoramidis Independently Predicts Improved Survival in TTR Amyloid Cardiomyopathy JACC Journals #Cardiology #CardioEd #Amyloidosis

Great to see this paper out in JACC Journals Establishing the role of transthyretin (prealbumin) as a surrogate of treatment effect of transthyretin stabilizers in ATTR-CM, such as acoramidis in this particular paper jacc.org/doi/epdf/10.10… #CardioTwitter

With all the recent news about ATTR therapies, it is good to remember that it is not a benign disease. Outcomes have tremendously improved, but still lots of work to do. pubmed.ncbi.nlm.nih.gov/40246387/ #cardiotwitter

Excited to have participated in this #Delphi study for the management of 🫀#sarcoidosis, just published in JACC Journals. Covers lots of controversial topics in #sarcoid management. sciencedirect.com/science/articl…

When Cassidy practiced medicine he fought to vaccinate kids against Hep B. But in a desperate attempt to be re-elected to the senate next year, he chose to betray what he believes and supported an opponent of vaccines for HHS Sec. That will be his legacy. theatlantic.com/health/archive…

High-Sensitivity Cardiac Troponin I for Risk Stratification in Wild-Type Transthyretin Amyloid Cardiomyopathy @matser89 AldostefanoPorcari Giacomo Tini Giulia Saturi Laura De Michieli Alberto Cipriani #AHAJournals ahajrnls.org/4mqUcOn

#3CT in action! Infinitely proud of our #HFC members #clinicaltrial #heartfailure #heartfailurecollaboratory

Bringing Inova Schar Heart and Vascular expertise to 3CT Shashank Sinha, MD, MSc, FACC, FAHA, FHFSA-Serial Shock Assessment Carolyn Rosner-Biomarkers/Patient Empowerment Christopher O'Connor Moderator, AHF Personalize Post-Discharge Mary Looby, Sophia Pan poster - Glucose control/ Cardiac Surgery Panels: Sumeet Singh Mitter, MD, MSc Mitchell Psotka